SSA Swiss Advisors AG Takes Position in Novo Nordisk A/S (NYSE:NVO)

SSA Swiss Advisors AG bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 47,056 shares of the company’s stock, valued at approximately $3,274,000. Novo Nordisk A/S makes up 1.7% of SSA Swiss Advisors AG’s holdings, making the stock its 21st biggest position.

Other large investors also recently made changes to their positions in the company. Bank of America Corp DE increased its position in shares of Novo Nordisk A/S by 8.1% in the fourth quarter. Bank of America Corp DE now owns 15,492,384 shares of the company’s stock worth $1,332,655,000 after acquiring an additional 1,165,955 shares in the last quarter. Folketrygdfondet boosted its stake in shares of Novo Nordisk A/S by 6.9% during the 1st quarter. Folketrygdfondet now owns 9,521,912 shares of the company’s stock valued at $661,202,000 after buying an additional 617,974 shares during the period. Renaissance Technologies LLC boosted its position in Novo Nordisk A/S by 1.5% during the fourth quarter. Renaissance Technologies LLC now owns 8,312,996 shares of the company’s stock valued at $715,084,000 after purchasing an additional 123,681 shares during the last quarter. Nuveen Asset Management LLC grew its stake in Novo Nordisk A/S by 73.2% in the fourth quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company’s stock valued at $537,189,000 after purchasing an additional 2,639,693 shares in the last quarter. Finally, Sustainable Growth Advisers LP increased its holdings in Novo Nordisk A/S by 3.8% in the first quarter. Sustainable Growth Advisers LP now owns 5,543,246 shares of the company’s stock worth $384,923,000 after buying an additional 202,443 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Wall Street Zen upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Saturday, June 14th. BNP Paribas started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an “underperform” rating on the stock. Guggenheim lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 17th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Finally, Hsbc Global Res raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, April 28th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $112.00.

Novo Nordisk A/S Stock Down 21.8%

Shares of NVO opened at $53.97 on Wednesday. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. The company has a 50-day moving average price of $70.43 and a two-hundred day moving average price of $73.37. The stock has a market cap of $240.98 billion, a price-to-earnings ratio of 15.97, a P/E/G ratio of 1.33 and a beta of 0.64. Novo Nordisk A/S has a 12 month low of $53.51 and a 12 month high of $139.74.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The firm had revenue of $11.87 billion for the quarter. Equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.